1.Clinical Characteristics of Anogenital Warts Among Patients Attending Genitourinary Medicine Clinic Hospital Kuala Lumpur Between 2015 and 2020
Khai Shin Tan ; Vijayaletchumi Krishnasamy ; Suganthi Thevarajah ; Min Moon Tang
Malaysian Journal of Dermatology 2022;48(Jun 2022):66-75
Background:
Anogenital human papillomavirus (HPV) is the most frequent reported sexually transmitted infection in
the world. We aim to describe the local demographic data and the clinical characteristics of anogenital
warts (AGWs).
Methods:
This is a retrospective study on all patients with AGWs who attended the GUM clinic between 2015
and 2020. Data was obtained from case notes and further analysed.
Results:
A total of 935 patients with AGWs attended the GUM clinic between 2015 and 2020. The mean
age was 30.4 years (range 12-84). The male to female ratio was 2.35:1. Majority were Malaysian
(97%). Majority of the Malaysian were Malays (61.5%) followed by Chinese (27.7%) and Indian
(8.9%). About 5.6% had a history of substance abuse. While the majority (57.9%) were heterosexual,
34.8% were homosexual and 6.4% were bisexual. About 59.8% had more than one sexual partner.
A quarter (25.6%) was infected with the human immunodeficiency virus. The most frequent site of
AGWs in males was the perianal area (52.6%), followed by the penis (45.7%), and with a fifth of
them having lesions at multiple sites. For female patients, the most frequent site of AGWs was the
posterior fourchette (45.2%) followed by the labia minora (33%) with 46.6% had involvement at
multiple sites. Approximately 17.6% had other concomitant sexually transmitted infections. Local
treatment application used included cryotherapy (86.4%), podophyllin (35.3%), tri-chloroacetic acid
(26.8%) and imiquimod (2.6%). About 41.5% required combination of these modalities. Nearly 6.2%
experienced recurrence. About 2% required surgical intervention.
Conclusions
AGWs was more commonly observed in male. The most frequent site of involvement was perianal for
male (52.6%) and posterior fourchette in female (45.2%).
Papillomavirus Infections
;
Sexually Transmitted Diseases
2.Analysis on human papillomavirus 16 and 18 types infection among 805 patients with common anorectal lesions.
Jian-xiang GENG ; Zhi-ming FAN ; Yi-jiang DING ; Jian-ning CHEN ; Su-min ZHANG ; Wei ZHOU ; Shu-liang HUANG ; Dian-mei HAN
Chinese Journal of Gastrointestinal Surgery 2011;14(12):958-960
OBJECTIVETo analyze the infection condition of human papillomavirus (HPV) type 16 and 18 in the squamous cells and columnar cells of patients with common anorecatal lesions.
METHODSInfections of HPV type 16 and 18 were determined with real-time fluorescent quantitative PCR in the wax-embedded surgical specimen of 805 patients with common anorectal diseases.
RESULTSThe overall infection rate among 805 patients with anorecatal lesions was 66.1% (532/805). The infection rate was 82.6% (95/115) in patients with mixed hemorrhoids, 76.5% (88/115) in anal papillary fibromas, 74.8% (86/115) in internal hemorrhoids, 72.2% (83/115) in fistulas, 69.6% (80/115) in external hemorrhoids, 47.8% (55/115) in anal perianal abscesses, and 39.1% (45/115) in anal fissures.
CONCLUSIONInfection rate of HPV type 16, 18 in common anorectal lesions is high.
Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Papillomavirus Infections ; Rectal Diseases ; epidemiology
4.Consideration on the construction of a special research database for human papillomavirus vaccination in high-risk and special populations.
Yuan Ying MA ; Jian Hu HE ; Shen Yu WANG ; Bing Qing LIU ; Xin Yu WANG
Chinese Journal of Preventive Medicine 2022;56(12):1702-1708
The application of human papillomavirus (HPV) vaccine in China has accelerated in recent year. Women's and Children's hospitals as well as general hospitals have established HPV vaccination counselling clinic in succession. A large amount of valuable preventive and clinical data have been generated in the evaluation, recommendation, immunization and management of HPV vaccine for high-risk and special populations. This article sorted out the operation process of HPV vaccination counselling clinic, discussed the methods for hospitals to construct a special research database for HPV vaccination in high-risk and special populations under different degrees of informatization. It also provided a reference for the establishment of unified data standards, the formation of available data resources, and the promotion of real world study on HPV vaccination for high-risk and special populations in China.
Child
;
Humans
;
Female
;
Papillomavirus Infections/prevention & control*
;
Human Papillomavirus Viruses
;
Papillomavirus Vaccines
;
Vaccination
;
Surveys and Questionnaires
;
Health Knowledge, Attitudes, Practice
5.Multidisciplinary Prevention and Control of Cervical Cancer:Application and Prospects.
Yan-Qin YU ; Jin-Qi HAO ; Hui-Fang XU ; Meng-Na WEI ; You-Lin QIAO
Acta Academiae Medicinae Sinicae 2020;42(4):535-539
Cervical cancer is the second most common malignant tumor in women worldwide.The burden of cervical cancer is particularly heavy in less developed countries as the malignancy brings huge pain to the patients and their family members and causes huge losses to social development and global health.However,cervical cancer is a preventable and curable disease.While screening and human papillomavirus vaccination in developed countries have remarkably lowered the incidence and mortality of cervical cancer,there is still a far way to go to achieve the prevention and treatment of this disease.The multidisciplinary prevention and control programs slightly differ in different countries due to diverse economic and health conditions.The general principle is to vaccinate the young females and to implement a comprehensive strategy including human papillomavirus vaccine vaccination,screening,early diagnosis,and early treatment in adults.
Early Detection of Cancer
;
Female
;
Humans
;
Papillomavirus Infections
;
Papillomavirus Vaccines
;
Uterine Cervical Neoplasms
;
prevention & control
;
Vaccination
6.A rare case of a primary signet-ring cell carcinoma of the cervix
Riezyl B. Culminas ; Aida J. Bautista ; Sabrina Ang-Sy
Philippine Journal of Obstetrics and Gynecology 2021;45(6):250-255
A 44‑year‑old woman presented with an abnormal vaginal discharge. She was initially diagnosed with cervical intraepithelial neoplasia‑1 through Papanicolaou smear and was managed with cryotherapy and completed human papillomavirus vaccinations. Nine years later, gynecologic examination showed a cervical mass, and biopsy revealed a signet‑ring cell‑type mucinous adenocarcinoma. Extensive systemic evaluation performed revealed no other malignancies. Radical hysterectomy was performed, and final pathology report showed a primary signet-ring cell cervical carcinoma stage 1B2. Concurrent chemotherapy with adjuvant external beam radiation therapy was then given. The patient has no evidence of disease for 24 months now since diagnosis. Primary signet‑ring cell carcinoma of the cervix is rare. It is diagnosed when no other tumor is found in extragenital sites, histology consists of signet‑ring morphology, tumor includes areas of adenocarcinoma in situ, and case has a prolonged survival. Overall patient education plays a vital role in management.
Papanicolaou Test
;
Papillomavirus Infections
;
Carcinoma, Signet Ring Cell
;
Human Papillomavirus Viruses
7.Human papillomavirus prevalence and type distribution in Chinese juvenile-onset recurrent respiratory papillomatosis patients.
Chang Chang DUN ; Yu Tong LI ; Xue Lian ZHAO ; Fang Hui ZHAO
Chinese Journal of Epidemiology 2023;44(6):990-998
Objective: To evaluate HPV prevalence and type distribution in Chinese juvenile-onset recurrent respiratory papillomatosis (JoRRP) patients. Methods: We searched China National Knowledge Infrastructure, Wanfang data, China Biology Medicine disc, PubMed, Embase, and the Cochrane Library for studies assessing HPV infection of Chinese JoRRP patients up to 1 October, 2022. Two authors independently performed literature selection, data extraction, and quality assessment. HPV prevalence and HPV type-specific prevalence were pooled using a random effects model after Freeman-Tukey double arcsine transformation. All analyses were performed with R 4.1.3 software. Results: Nineteen publications investigating HPV infection of JoRRP patients were included in the final analyses. Of these, 16 studies reported HPV prevalence with a sample size of 1 528 patients, and 11 studies reported HPV6 prevalence and HPV11 prevalence with a sample size of 611 patients. All studies were graded as medium quality. In Chinese JoRRP patients, the synthesized HPV prevalence was 92.0% (95%CI:86.0%-96.6%, I2=87%), HPV6 prevalence was 42.4% (95%CI:34.9%-50.1%, I2=61%), and HPV11 prevalence was 72.3% (95%CI:59.0%-83.9%, I2=87%). All the pooled prevalence persisted in subgroup analyses stratified by publication year, sample size, and specimen type (P>0.05). There was no evidence of publication bias. In Chinese JoRRP patients, HPV16, 18, 31, 33, 52, and 58 prevalence was very low. Conclusions: Our findings suggested high HPV prevalence in Chinese JoRRP patients, and the most common HPV types were HPV6 and HPV11.
Humans
;
Papillomavirus Infections/epidemiology*
;
Human Papillomavirus Viruses
;
East Asian People
;
Prevalence
8.Current status of clinical trials of HPV therapeutic vaccines.
Chinese Journal of Preventive Medicine 2023;57(10):1647-1654
Cervical cancer mainly caused by human papillomavirus (HPV) infection has become a public health issue, which seriously threatens women 's health. To prevent HPV infection, the currently used prophylactic vaccines mainly induce a humoral immune response in the host, thereby generating neutralizing antibodies. In contrast, the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host, primarily driven by Th1 cells, aiming to clear existing viral infections and slow down or inhibit tumor progression. Currently, several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials. This review will summarize the progress of these clinical trials, providing reference for the research and development of therapeutic HPV vaccines.
Female
;
Humans
;
Papillomavirus Vaccines/therapeutic use*
;
Papillomavirus Infections/prevention & control*
;
Uterine Cervical Neoplasms
;
Immunity, Cellular
;
Papillomaviridae
9.Investigation and analysis on the establishment and operation of adult vaccination clinics in Shandong Province.
Ren Peng LI ; Yang YU ; Wei Yan ZHANG ; Ying Jie ZHANG ; Hui Feng SUN ; Ai Qiang XU
Chinese Journal of Preventive Medicine 2023;57(12):2043-2049
Objective: To understand the setting of adult vaccination clinics and the situation of adult vaccination in Shandong province, and provide the date basis for the construction and development of adult vaccination clinics in Shandong province. Methods: Multi-stage stratified cluster random sampling was used to survey the settings, personnel allocation, operation status, and adult vaccination status of child-adult vaccination clinics and adult vaccination clinics. A random sampling survey was conducted for hydrophobia vaccination clinics in 12 counties (cities, districts) of Shandong province. The settings and vaccination status of different types of adult vaccination clinics were compared and analyzed using analysis of variance or χ2-test. Results: Among the investigated counties (cities, districts), the child-adult vaccination clinics, the adult vaccination clinics, and the hydrophobia vaccination clinics accounted for 59.51%, 7.97% and 32.52%, respectively. The construction model could be divided into three models: child-adult vaccination clinic model, child-adult and hydrophobia vaccination clinic model, child-adult, adult and hydrophobia vaccination clinic model. The child-adult vaccination clinics had been set up for a long time (≥3 years accounted for 94.33%) and were set up by public primary medical institutions (public institutions accounted for 93.81% and primary institutions accounted for 92.78%). Each vaccination clinic was equipped with full-time and part-time staff of (3.19±3.01) and (3.72±4.32). The adult vaccination clinics had been set up for a short time (≥3 years accounted for 94.33%) and were set up by public/private primary/secondary medical institutions in urban areas (urban areas accounted for 100%, primary institutions accounted for 69.23%, and private institutions accounted for 57.69%). Each vaccination clinic was equipped with full-time and part-time staff of (2.46±2.87) and (3.08±3.53). The coverage of influenza vaccine (InfV), human papillomavirus vaccine (HPV) and hepatitis B vaccine (Hep B) reached 100%, 98.45% and 97.42% in children-adult vaccination clinics, and 88.46%, 84.62% and 73.08% in adult vaccination clinics, respectively. The hydrophobia vaccination clinics only provided rabies vaccine for human use (RabV) and tetanus vaccine (TV) vaccination simultaneously. A total of 819.8 thousand doses of adult vaccines were administered in 2021. The adult inoculation doses of RabV, lnfV and HPV accounted for 42.60%, 27.47% and 17.54% of the total inoculation doses, respectively. The inoculation doses of InfV, HPV and RabV accounted for 49.33%, 21.97% and 13.80% of child-adult vaccination clinics, respectively. The inoculation doses of HPV, HepB and RabV accounted for 49.36%, 15.40% and 14.71% of adult vaccination clinics, respectively. The proportion of RabV reached 94.44% in the hydrophobia vaccination clinics alone. Conclusion: Adult vaccination is at the initial stage in Shandong province. The children's vaccination clinic is mainly responsible for adult vaccination. The variety of adult vaccines is relatively concentrated, and the adult vaccination rate is lower. The construction and publicity of adult vaccination should be further strengthened.
Adult
;
Humans
;
Papillomavirus Infections
;
Rabies
;
Influenza Vaccines
;
Vaccination
;
Ambulatory Care Facilities
;
Papillomavirus Vaccines
10.Current status of vaccination services for adults in urban and rural areas of nine provinces in China from 2019 to 2021.
Ru Yue HU ; Li Jun LIU ; Xi Xi ZHANG ; Qi Min ZENG ; Chang Sha XU ; Jia Kai YE ; Lei CAO ; Li LI ; Yi Fan SONG ; Zhao Nan ZHANG ; Wen Zhou YU
Chinese Journal of Preventive Medicine 2023;57(12):2050-2055
Objective: To understand the current situation of vaccination services for adults in China, explore how to establish a stable and efficient vaccination service system for adults, and provide reference for formulating corresponding policies. Methods: The vaccination information systems of nine provinces in China were used to obtain information on urban and rural vaccination of influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), and human papillomavirus vaccine (HPV) from 2019 to 2021. The indicator, vaccination rate/full vaccination rate, was used for statistical description. Results: The vaccination rate/full vaccination rate of the three vaccines in eastern China was generally higher than that in central and western China. The vaccination rate/full vaccination rate in urban areas was generally higher than that in rural areas. From 2019 to 2021, the vaccination rates of influenza vaccine among people aged 60 years and above in urban and rural areas were 2.96%, 6.29%, 6.14% and 1.29%, 2.58%, 2.94%, respectively. The vaccination rates of the PPV23 among people aged 60 years and above in urban and rural areas increased year by year, with rates of 0.38%, 1.05%, 1.15% and 0.14%, 0.49%, 0.59%, respectively. From 2019 to 2021, the HPV coverage of female adults aged 27-45 years in urban and rural areas increased year by year, with rates of 0.46%, 0.93%, 1.88% and 0.17%, 0.40%, 1.08%, respectively. Conclusion: The vaccination rates of influenza vaccine,PPV23 vaccine and HPV vaccine for adults in China are relatively low, with higher rates in the eastern region than in the central and western regions, and higher rates in urban areas than in rural areas. It is recommended to formulate corresponding health and economic policies and explore a suitable vaccination service system for adults in China to improve vaccination rates.
Adult
;
Female
;
Humans
;
Influenza Vaccines/therapeutic use*
;
Papillomavirus Infections
;
Vaccination
;
China
;
Papillomavirus Vaccines/therapeutic use*